Long-term (Up to ~5 Years) Outcomes Trial for People With Metabolic “Fatty” Liver Disease and Liver Fibrosis

Written By Patrick Smith

Are you living with metabolic fatty liver disease (also called MASLD)? 

If so, you may be eligible to participate in a clinical research study evaluating the GLP-1 medicines retatrutide and tirzepatide (Zepbound®) for the prevention of long-term complications of metabolic liver disease. 

ABOUT THE STUDY 

This is a Phase 3 study evaluating how retatrutide and tirzepatide (Zepbound) may slow the progression of high-risk metabolic fatty liver disease (MASLD) and help prevent serious liver complications. 

WHO MAY QUALIFY? 

You may be eligible to participate if you meet all the following: 

  • Age 18 years or older 

  • Body mass index (BMI) of 25 or higher (classified as overweight or obesity) 

  • Do not drink more than an average of 3 alcoholic drinks per day (for men) or 2 per day (for women) 

  • Have not used any GLP-1-based medication — including pills or injections (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo) within the past 6 months 

  • Have not used any other weight loss medication within the past 3 months 

  • Have never had surgery for treatment of obesity 

  • If diagnosed with type 2 diabetes, have an HbA1c of less than 10% 

INTERESTED IN LEARNING MORE?

Click below to complete a short questionnaire to see if you may be eligible.

SEE IF YOU QUALIFY

Study Sponsor: Eli Lilly and Company

ClinicalTrials.gov ID: NCT07165028; https://clinicaltrials.gov/study/NCT07165028

Patrick Smith